A new Cambridge, Mass.-based startup, Thrive Earlier Detection (“Thrive” for short), has raised $110 million to develop a much-watched blood test that aims to detect cancer when it is still soon enough to remove it.

The company, whose existence STAT first reported on May 8, is entering a crowded field flooded with money. Grail, based in San Francisco, has raised $1.5 billion on a similar effort. According to Pitchbook, Grail is valued at $3.1 billion, and it will present data at cancer meeting this weekend. Other companies, including Guardant and Exact Sciences (one of Thrive’s investors) have expressed interest in the field of cancer detection via blood test, known as liquid biopsy.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy